Home | All trials

[RDF data]
Trial NCT00000482

Resource URI: http://static.linkedct.org/resource/trials/NCT00000482
PropertyValue
linkedct:brief_title Coronary Drug Project
linkedct:condition <http://static.linkedct.org/resource/condition/2312>
linkedct:condition <http://static.linkedct.org/resource/condition/3388>
linkedct:condition <http://static.linkedct.org/resource/condition/5702>
linkedct:condition <http://static.linkedct.org/resource/condition/8483>
linkedct:condition <http://static.linkedct.org/resource/condition/8489>
linkedct:criteria Men, ages 30-64. Three months beyond most recent myocardial infarction.
linkedct:description BACKGROUND: Correlation of high levels of serum cholesterol with an increased incidence and prevalence of coronary heart disease (CHD) was demonstrated--prior to the inception of the Coronary Drug Project--repeatedly in prospective and cross-sectional epidemiological surveys (e.g., the Tecumseh Study, the Framingham Heart Disease Study). These findings led to the question of whether long-term lowering of serum lipids in individuals both with and without CHD would have a beneficial effect on morbidity and mortality. The Coronary Drug Project was designed to answer the question of secondary prevention. In 1961, Dr. Robert Wilkins (Boston University School of Medicine) chaired an ad hoc committee which determined the desirability and feasibility of the conduct of this study. Following National Heart Advisory Council (NHAC) support, a study Policy Board, Steering Committee, and Coordinating Center were established and a detailed protocol was written. In 1964, NHAC approved the project and the NHI recommendation for implementation; the study was begun in 1965. Supported by the grant mechanism, the trial involved 53 participating clinics, a coordinating center, central laboratory, ECG center, drug procurement and distribution center, and NHI medical liaison office, and a policy board, steering committee, and 12 other committees (e.g., a data and safety monitoring committee). The first patient was randomly allocated to treatment in March 1966 and the last in October 1969. Each patient reported to the clinic every 4 months for a follow-up visit. DESIGN NARRATIVE: Randomized, double-blind, fixed sample. A total of 8,341 patients were randomly assigned to six treatment groups consisting of 2.5 mg/day of conjugated estrogens, 5.0 mg/day of conjugated estrogens, 1.8 gm/day of clofibrate, 6.0 mg/day of dextrothyroxine sodium, 3.0 gm/day of niacin, or 3.8 gm/day of lactose placebo.
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Male
linkedct:eligibility_healthy_volunteers No
linkedct:eligibility_maximum_age 64 Years
linkedct:eligibility_minimum_age 30 Years
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date October 27, 1999
linkedct:id NCT00000482
rdfs:label Trial NCT00000482
linkedct:lastchanged_date June 23, 2005
linkedct:lead_sponsor_agency National Heart, Lung, and Blood Institute (NHLBI)
linkedct:nct_id NCT00000482
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:org_study_id 1
linkedct:overall_official <http://static.linkedct.org/resource/overall_official/45660>
linkedct:overall_status Completed
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000482>
linkedct:phase Phase 3
linkedct:reference <http://static.linkedct.org/resource/reference/11991>
linkedct:reference <http://static.linkedct.org/resource/reference/1602>
linkedct:reference <http://static.linkedct.org/resource/reference/2689>
linkedct:reference <http://static.linkedct.org/resource/reference/37580>
linkedct:reference <http://static.linkedct.org/resource/reference/40584>
linkedct:reference <http://static.linkedct.org/resource/reference/40590>
linkedct:reference <http://static.linkedct.org/resource/reference/41119>
linkedct:reference <http://static.linkedct.org/resource/reference/41136>
linkedct:reference <http://static.linkedct.org/resource/reference/41307>
linkedct:reference <http://static.linkedct.org/resource/reference/42346>
linkedct:reference <http://static.linkedct.org/resource/reference/42349>
linkedct:reference <http://static.linkedct.org/resource/reference/42358>
linkedct:reference <http://static.linkedct.org/resource/reference/42410>
linkedct:reference <http://static.linkedct.org/resource/reference/42429>
linkedct:reference <http://static.linkedct.org/resource/reference/42437>
linkedct:reference <http://static.linkedct.org/resource/reference/42448>
linkedct:reference <http://static.linkedct.org/resource/reference/42534>
linkedct:reference <http://static.linkedct.org/resource/reference/42552>
linkedct:reference <http://static.linkedct.org/resource/reference/43106>
linkedct:reference <http://static.linkedct.org/resource/reference/43538>
linkedct:reference <http://static.linkedct.org/resource/reference/43899>
linkedct:reference <http://static.linkedct.org/resource/reference/43938>
linkedct:reference <http://static.linkedct.org/resource/reference/44159>
linkedct:reference <http://static.linkedct.org/resource/reference/44161>
linkedct:reference <http://static.linkedct.org/resource/reference/44170>
linkedct:reference <http://static.linkedct.org/resource/reference/44333>
linkedct:reference <http://static.linkedct.org/resource/reference/44513>
linkedct:reference <http://static.linkedct.org/resource/reference/46616>
linkedct:reference <http://static.linkedct.org/resource/reference/54236>
linkedct:reference <http://static.linkedct.org/resource/reference/7548>
linkedct:reference <http://static.linkedct.org/resource/reference/810>
linkedct:reference <http://static.linkedct.org/resource/reference/811>
linkedct:reference <http://static.linkedct.org/resource/reference/812>
linkedct:reference <http://static.linkedct.org/resource/reference/813>
linkedct:reference <http://static.linkedct.org/resource/reference/814>
linkedct:reference <http://static.linkedct.org/resource/reference/815>
linkedct:source National Heart, Lung, and Blood Institute (NHLBI)
linkedct:start_date April 1965
linkedct:study_design Prevention, Randomized, Double-Blind, Placebo Control
linkedct:study_type Interventional
linkedct:summary To determine whether regular administration of lipid modifying drugs (clofibrate, nicotinic acid, estrogen, dextrothyroxine) to men with a documented myocardial infarction would result in significant reduction in total mortality over a five year period. Secondarily, to determine whether the degree to which these drugs changed serum lipids was correlated with any effect on mortality and morbidity rates; to gain further information on the long-term prognosis of myocardial infarction (by studying the control group as intensively as the treatment group); to acquire further experience and knowledge concerning the techniques and methodology of long-term clinical trials; to determine, in a substudy, the effectiveness of aspirin, a platelet inhibitor, in reducing recurrences of myocardial infarction.
rdf:type linkedct:trials
linkedct:verification_date July 2004